FluroTech Receives Good Manufacturing Practice Validation of the CompleTest(TM) Cannabinoid Assays for THCa and CBDa
Calgary, Alberta--(Newsfile Corp. - September 25, 2018) - FluroTech Ltd. (TSXV: TEST), ("FluroTech" or the "Company"), is pleased to report that preliminary Good Manufacturing Practice ("GMP") validation testing, done by the Drug Development and Innovation Center at the University of Alberta, of the CompleTest™ cannabinoid assays for THCa and CBDa were recorded at less than 2% difference when compared to the industry quality control standard High Performance Liquid Chromatography ("HPLC") technology.
HPLC analytic equipment is considered highly technical to operate and reasonably expensive to purchase with measurement results that are relatively slow. The use of the CompleTest™ provides a tremendous opportunity for cultivators to benefit from FluroTech's technology providing ease of use, rapid measurement, high accuracy and low operating cost.
"This is a tool that no modern medical cannabis cultivator can go without. It takes all the guess work out of crop production," stated, Dr. MacMillan, Director of Scientific Research and Business Development.
FluroTech's technology provides an evidence-based solution for making critical operational decisions related to chemotypic plant screening and selection, breeding or determining the optimal time to harvest crops to maximize cannabinoid concentrations.